Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that third quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, November 5th.
Covered in this story
What has happened since
- Organogenesis Holdings Inc Class a is down 16.3% since this was published, 10 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ORGO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Organogenesis Holdings Inc Class a →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.